{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:02:08Z","timestamp":1792789328773,"version":"4.5.0"},"reference-count":77,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Health","award":["1R15CA290481-01A1"],"award-info":[{"award-number":["1R15CA290481-01A1"]}]},{"name":"National Institute of Health","award":["1R16GM153547-01"],"award-info":[{"award-number":["1R16GM153547-01"]}]},{"name":"CMSRU","id":[{"id":"https:\/\/ror.org\/007evha27","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Acute myeloid leukemia (AML) is cytogenetically and phenotypically heterogeneous, and this diversity contributes to differences in how patients respond to therapies that target apoptosis. Venetoclax, a selective BCL-2 inhibitor, has been demonstrated to improve outcomes when combined with hypomethylating drugs (HMAs) such as azacitidine or decitabine; nonetheless, clinical trials have indicated that resistance and recurrence are prevalent. This review examines the current evidence linking chromosomal abnormalities and cellular differentiation state to mitochondrial apoptotic pathways, with an emphasis on how these factors influence dependence on certain anti-apoptotic BCL-2 family proteins. We summarize how specific cytogenetic subtypes and high-risk groups (including monosomy 7\/del(7q) and complex karyotype\/TP53-altered AML) frequently show stress-adaptive signaling and reliance on multiple anti-apoptotic pathways, which can limit the durability of response to BCL-2 inhibition. Lineage-associated dependencies are also examined, such as monocytic differentiation (which leads to increased MCL-1 reliance) and erythroid\/megakaryocytic differentiation, which has been associated with increased BCL-XL dependence and venetoclax resistance. Finally, we discuss the therapeutic implications of dependence mapping, including venetoclax combinations and direct MCL-1\/BCL-XL targeting, and propose promising biomarker strategies that can detect dependence shifts early and guide appropriate treatment selection.<\/jats:p>","DOI":"10.3390\/genes17091122","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:23:53Z","timestamp":1789496633000},"page":"1122","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Wired to Survive: How AML Cytogenetics Shape Apoptotic Dependence and Venetoclax Resistance"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9041-6525","authenticated-orcid":false,"given":"Arnold","family":"Rojas","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7899-4408","authenticated-orcid":false,"given":"Sahil","family":"Jethi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6498-9119","authenticated-orcid":false,"given":"Tulin","family":"Budak-Alpdogan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cooper University Hospital, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2767-2929","authenticated-orcid":false,"given":"Manoj K.","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: The 2024 ELN recommendations","volume":"144","author":"DiNardo","year":"2024","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/oncolo\/oyac135","article-title":"Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US","volume":"27","author":"Vachhani","year":"2022","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Dufva","year":"2023","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine\/Venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1182\/blood-2022-167352","article-title":"Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study","volume":"140","author":"Kohlschmidt","year":"2022","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_13","unstructured":"Chang, C.-C., and Kuzu, A. (2023). What\u2019s New in AML Classification (WHO 2022 vs International Consensus Classification), College of American Pathologists. Available online: https:\/\/www.cap.org\/member-resources\/articles\/whats-new-in-aml-classification-who-2022-vs-international-consensus-classification."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mr\u00f3zek, K. (2022). Molecular cytogenetics in acute myeloid leukemia in adult patients: Practical implications. Pol. Arch. Intern. Med., 132.","DOI":"10.20452\/pamw.16300"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Qian, S., Wei, Z., Yang, W., Huang, J., Yang, Y., and Wang, J. (2022). The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.985363"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: From apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wei, Y., Cao, Y., Sun, R., Cheng, L., Xiong, X., Jin, X., He, X., Lu, W., and Zhao, M. (2020). Targeting Bcl-2 Proteins in Acute Myeloid Leukemia. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.584974"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","article-title":"BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents","volume":"12","author":"Deng","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 inhibitors for hematologic malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Garciaz, S., Saillard, C., Hicheri, Y., Hospital, M.A., and Vey, N. (2021). Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance. Cancers, 13.","DOI":"10.3390\/cancers13225608"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nyas.13038","article-title":"Multiple myeloma in the marrow: Pathogenesis and treatments","volume":"1364","author":"Fairfield","year":"2016","journal-title":"Ann. N. Y Acad. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101117","DOI":"10.1016\/j.blre.2023.101117","article-title":"The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment","volume":"62","author":"Darwish","year":"2023","journal-title":"Blood Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-142780","article-title":"Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)","volume":"136","author":"Arslan","year":"2020","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41408-023-00928-1","article-title":"Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","article-title":"Insights into KMT2A rearrangements in acute myeloid leukemia: From molecular characteristics to targeted therapies","volume":"13","author":"Zehtabcheh","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/hematology.2025000755","article-title":"The promise of menin inhibitors: From approval to triplet regimens","volume":"2025","author":"Thakur","year":"2025","journal-title":"Hematology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41375-024-02400-w","article-title":"Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines","volume":"39","author":"Gress","year":"2025","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1158\/2643-3230.BCD-24-0212","article-title":"Combination Strategies with Menin Inhibitors for Acute Leukemia","volume":"6","author":"Issa","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO-25-00914","article-title":"Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML","volume":"43","author":"Zeidner","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1080\/10428194.2022.2118533","article-title":"Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment","volume":"63","author":"Abbas","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ajh.26589","article-title":"Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms","volume":"97","author":"Shah","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1111\/febs.14122","article-title":"Control of cell death and mitochondrial fission by ERK1\/2 MAP kinase signalling","volume":"284","author":"Cook","year":"2017","journal-title":"FEBS J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41408-024-01186-5","article-title":"What have we learned about TP53-mutated acute myeloid leukemia?","volume":"14","author":"Shahzad","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100017","DOI":"10.1016\/j.bneo.2024.100017","article-title":"Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS","volume":"1","author":"Othman","year":"2024","journal-title":"Blood Neoplasia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","article-title":"Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy","volume":"160","author":"Montero","year":"2015","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.2021013156","article-title":"Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2","volume":"139","author":"Mill","year":"2022","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/joim.13581","article-title":"Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia","volume":"293","author":"Weng","year":"2023","journal-title":"J. Intern. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41408-021-00541-0","article-title":"ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine","volume":"11","author":"Rahmani","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","article-title":"Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia","volume":"38","author":"Bhatt","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Liu, J., Chen, Y., Yu, L., and Yang, L. (2022). Mechanisms of venetoclax resistance and solutions. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1005659"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD\u2013specific STAT5 activation","volume":"114","author":"Yoshimoto","year":"2009","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","article-title":"Saga of Mcl-1: Regulation from transcription to degradation","volume":"27","author":"Senichkin","year":"2020","journal-title":"Cell Death Differ."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1158\/1078-0432.CCR-24-0028","article-title":"A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed\/Refractory Hematologic Malignancies","volume":"30","author":"Desai","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: Mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood.2022017341","article-title":"Mechanisms of resistance to venetoclax","volume":"140","author":"Condoluci","year":"2022","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Nifoussi, S.K., Vrana, J.A., Domina, A.M., De Biasio, A., Gui, J., Gregory, M.A., Hann, S.R., and Craig, R.W. (2012). Thr 163 Phosphorylation Causes Mcl-1 Stabilization when Degradation Is Independent of the Adjacent GSK3-Targeted Phosphodegron, Promoting Drug Resistance in Cancer. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047060"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/leu.2012.180","article-title":"Downregulation of Mcl-1 through GSK-3\u03b2 activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"key":"ref_56","first-page":"1034","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Zhang","year":"2021","journal-title":"Haematologica"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","article-title":"Bone marrow microenvironment\u2013derived signals induce Mcl-1 dependence in multiple myeloma","volume":"129","author":"Gupta","year":"2017","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Leverson, J.D., and Cojocari, D. (2018). Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00458"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood-2016-02-699363","article-title":"JAK1\/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell\u2013induced protection of AML","volume":"130","author":"Karjalainen","year":"2017","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1182\/blood-2025-5250","article-title":"Venetoclax dosages, BH3 profiling, and bcl-2 expression predict response to azacitidine + venetoclax regimen in first line AML not eligible to intensive chemotherapy: First results of venetacible study","volume":"146","author":"Cluzeau","year":"2025","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","volume":"140","author":"Janssen","year":"2022","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed\/Refractory Acute Myeloid Leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bjh.19314","article-title":"Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights","volume":"204","author":"Nachmias","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e1721","DOI":"10.1038\/cddis.2015.97","article-title":"BCL-2 is dispensable for thrombopoiesis and platelet survival","volume":"6","author":"Debrincat","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-025-01753-8","article-title":"First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed\/refractory solid malignancies","volume":"18","author":"Mahadevan","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"eado7120","DOI":"10.1126\/sciadv.ado7120","article-title":"BCL-XL-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors","volume":"10","author":"Judd","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","article-title":"BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions","volume":"332","author":"Letai","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_72","unstructured":"National Library of Medicine (US) (2026, March 15). ClinicalTrials.gov: Clinical Studies Involving Venetoclax in Acute Myeloid Leukemia, Available online: https:\/\/clinicaltrials.gov\/search?cond=Acute%20Myeloid%20Leukemia&intr=venetoclax."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Minihane, E.-J., Krotee, L., Wu, J., Thornton, L., Fell, G., Herter, S., Ryan, J., Jakkani, A., Marinchev, K., and Lane, A.A. (2025). Dynamic BH3 profiling predicts clinical outcomes in acute myeloid leukemia. bioRxiv.","DOI":"10.1101\/2025.10.14.682414"},{"key":"ref_74","unstructured":"Staff, N. (2026, January 04). Drug Combination May Target the Unique Metabolism of Leukemia Stem Cells, Available online: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2018\/aml-venetoclax-azacitidine-target-leukemia-stem-cells?cid=eb_govdel."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"17914","DOI":"10.1002\/cam4.6430","article-title":"Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre- versus post-VIALE-A real-world experience from a predominantly US community setting","volume":"12","author":"Vachhani","year":"2023","journal-title":"Cancer Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41408-025-01270-4","article-title":"Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days","volume":"15","author":"Gangat","year":"2025","journal-title":"Blood Cancer J."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/9\/1122\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:32:50Z","timestamp":1789497170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/9\/1122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":77,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["genes17091122"],"URL":"https:\/\/doi.org\/10.3390\/genes17091122","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}